Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Crocs, Inc. (CROX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Crocs, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Crocs, Inc. trades at $132 (market cap $6.63B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Crocs, Inc. nearer its low. Which is the better fit depends on your goals.
| BIO | CROX | |
|---|---|---|
Market Cap | $9.39B | $6.63B |
Sector | Health | Consumer Staples |
52-Week High | $354.54 | $141.19 |
52-Week Low | $241.71 | $73.39 |
Enterprise Value | $9.14B | $8.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Crocs (CROX) trades at $136.62, up 1.82% with strong technical momentum and bullish moving averages. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $4.55 exceeding expectations. Despite a net loss in 2025 due to tax impacts, profitability metrics remain robust with 57.47% gross margins and 42.3% ROE. Recent news highlights tax strategy scrutiny but also strong DTC growth and raised 2026 guidance.
The stock presents value with a 12.12 P/E ratio below industry averages, supported by analyst consensus of $140.43 price target. Key risks include HEYDUDE brand weakness, tariff pressures, and ongoing tax scrutiny. Upside potential exists from international expansion and direct-to-consumer growth, though near-term volatility may persist around earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Crocs, Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →
